Saturation of striatal D2 dopamine receptors by clozapine

International Journal of Neuropsychopharmacology

Volumn 5, Issue 1, 2002, Pages 11-16

  Nyberg, Svante ^a,b   Chou, Yuan Hwa ^a   Halldin, Christer ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

11C raclopide; Clozapine; D2 dopamine receptor; Positron emission tomography

Indexed keywords

CARBON 11; CLOZAPINE; DOPAMINE 2 RECEPTOR; RACLOPRIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCULATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; EQUILIBRIUM CONSTANT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MATHEMATICAL ANALYSIS; MONKEY; NONHUMAN; OXYGEN SATURATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; VALIDATION PROCESS;

ALGORITHMS; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; NEOSTRIATUM; PILOT PROJECTS; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036128497     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145701002693     Document Type: Article

References (29)

1. Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin 1A receptors
2. Clozapine. A novel antipsychotic agent
3. Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection
4. Pharmacokinetics of clozapine and risperidone: A review of recent literature
5. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
6. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients
7. A PET study of D1-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain
8. 2-dopamine receptors studied by PET - A comparison to the equilibrium analysis
9. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET
10. 11C]raclopride in man
11. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - Relation to extrapyramidal side effects
12. D1-and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics
13. 2 dopamine receptors in neuroleptic-naive schizophrenic patients
14. Clozapine dose in the United States and Europe: Implications for therapeutic and adverse effects
15. 11C]raclopride binding to D2-dopamine receptors in the monkey brain
16. A comparative PET-study of five carbon-11 or fluorine-18 labeled salicylamides. Preparation and in vitro dopamine D-2 binding
17. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking
18. Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [C-11]raclopride binding
19. Clozapine for the treatment-resistant schizophrenic
20. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
21. 1-dopamine receptor
22. Plasma clozapine concentrations as a predictor of clinical response: A follow-up study
23. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients
24. D2- and 5-HT2 receptor occupancy in high-dose neuroleptic treated schizophrenic patients
25. 11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients
26. Clozapine occupies high levels of dopamine D2 receptors
27. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
28. The ECAT EXACT HR: Performance of a new high resolution positron scanner
29. Dopamine receptor occupancy and plasma haloperidol levels